Multi Cancer Early Detection Market Size, Share, Trends, Growth 2034

Multi Cancer Early Detection Industry Prospective:

The global multi cancer early detection market size was worth around USD 978.56 million in 2024 and is predicted to grow to around USD 4,170.29 million by 2034, with a compound annual growth rate (CAGR) of roughly 15.60% between 2025 and 2034.

Request Free Sample

Multi Cancer Early Detection Market: Overview

Multi-cancer early detection tests refer to a series of medical interventions aimed at diagnosing multiple types of cancer at early stages. According to industry research, multi-cancer early detection can serve as an effective test for improving cancer care around the globe.

The blood tests conducted as a part of a multi-cancer early detection program aim to detect and identify biomarkers generally associated with cancer cells before conventional methods of cancer detection.

Multi-cancer early detection (MCED) tests are currently in the development stage, but they are expected to become complementary and first-line diagnostic tools for the fatal disease.

The demand for MCED tests has grown over the years, primarily driven by the increasing number of cancer patients worldwide. The rising investments in cancer research and infrastructure development to support revolutionary innovation in multi-cancer early detection may further help the industry thrive in the forecast period.

One of the major drawbacks of the multi cancer early detection industry is the lack of existing globally accepted MCED tests. Additionally, multi cancer early detection techniques are considered complementary diagnostic tools, and patients may have to undergo additional tests.

Key Insights:

• As per the analysis shared by our research analyst, the global multi cancer early detection market is estimated to grow annually at a CAGR of around 15.60% over the forecast period (2025-2034)
• In terms of revenue, the global multi cancer early detection market size was valued at around USD 978.56 million in 2024 and is projected to reach USD 4,170.29 million by 2034.
• The multi cancer early detection market is projected to grow at a significant rate due to the increasing number of cancer patients worldwide.
• Based on the end-use, the hospital segment is growing at a high rate and will continue to dominate the global market as per industry projections.
• Based on the type, the circulating tumor DNA (ctDNA)-based tests segment is anticipated to command the largest market share.
• Based on region, North America is projected to dominate the global market during the forecast period.

Multi Cancer Early Detection Market: Growth Drivers

Increasing number of cancer patients worldwide to drive market demand rate

The global multi cancer early detection market is expected to be driven by the growing number of cancer patients across the globe.

According to the World Health Organization (WHO), cancer has become a leading cause of medically-related deaths worldwide. The disease accounted for nearly 10 million deaths in 2020, and the number has been growing since then.

Cancer is caused when normal cells convert into cancerous cells and multiply rapidly, killing other healthy cells in the body. Cancer experts claim that currently the world population is affected by more than 100 types of cancer, making them difficult to diagnose, especially at early stages. Cancers are broadly classified into three types: blood cancers, solid cancers, and mixed cancers.

As per statistics published by the National Cancer Institute, cancer mortality is around 146.0 per 100,000 men and women per year. Research has concluded that the chances of preventing death due to cancer are higher if the disease is detected at early stages. Cleveland Clinic suggests that most cancers can be cured at stage 0, depending on the patient’s overall health.

The lack of effective cure and treatment for cancer at later stages has created more demand for diagnostic tools that can detect the presence of the disease at early stages, improving the chance of survival among patients.

Rising investments in cancer research and associated medical care programs to propel the industry’s growth rate

The burgeoning pressure on the global healthcare systems, mainly affected by cancer-related medical care, has encouraged more investments in cancer research.

In addition, the increasing inauguration of new healthcare facilities, especially for diagnosing, treating, and managing cancer patients, will further generate growth opportunities for the global multi cancer early detection industry players.

In March 2025, the US witnessed the launch of several new initiatives aimed at improving cancer research and care in the country, such as the Cancer AI Alliance, ARPA-H's Advanced Analysis for Precision Cancer Therapy (ADAPT) program, and others.

Multi Cancer Early Detection Market: Restraints

Early stages of development and a lack of standard tests to limit the market’s expansion rate

The global multi cancer early detection industry is projected to be restricted by the lack of existing tests on a commercial scale. Market study suggests that although multi cancer early detection technologies are currently being used in some parts of the world, they are not adopted across all clinics worldwide, limiting the use of the tests.

In addition to this, most MCED tests are still under development pending approvals from regulatory bodies. Until MCED tests can be made available on a large scale worldwide, their growth potential will continue to be limited in terms of revenue.

Multi Cancer Early Detection Market: Opportunities

Ongoing advancements and increasing regulatory approvals to generate growth opportunities in the future

The global multi cancer early detection market is expected to generate growth opportunities due to the ongoing advancements in the industry. For instance, Exact Sciences, a US-based biotechnology company, is currently working on the development of the Cancerguard™ test. Exact Sciences is aiming to revolutionize cancer detection and treatment with the launch of the new multi-cancer early detection tool that can identify different types of cancer using a single blood draw.

In addition, two emerging technologies that have gained widespread attention in the medical world include CancerSEEK by Exact Sciences and Galleri Test by GRAIL INC. These MCED tests currently use computational algorithms with artificial intelligence, next-generation sequencing, and molecular analysis of blood samples for detecting early signs of several types of cancer.

In February 2025, GRAIL announced a partnership with actress Kate Walsh for the launch of Generation Possible. The educational project is developed to generate more awareness around multi cancer early detection. This, in turn, will create more revenue for MCED tests and diagnosis even in remote parts of the world.

Multi Cancer Early Detection Market: Challenges

Ineffectiveness of MCED in diagnosing certain cancers remains a major challenge for industry players

The global multi cancer early detection industry is projected to be challenged by the ineffectiveness of MCED in detecting certain types of cancers. According to medical experts, certain cancers can only be detected in early stages, and MCED may not prove beneficial in such cases. In addition to this, the risk of false positives or negatives can put the lives of patients at risk, impacting the overall growth trends of the industry.

Request Free Sample

Multi Cancer Early Detection Market: Report Scope

Multi Cancer Early Detection Market: Segmentation

The global multi cancer early detection market is segmented based on end-user, type, and region.

Based on the end-use, the global market segments are diagnostic laboratories, hospitals, and others. In 2024, the highest growth was listed in the hospitals segment, which held control over 49% of the market share. The growing adoption of advanced technologies in hospitals, especially for cancer care and treatment, is fueling the segmental revenue.

In addition to this, hospitals are well equipped financially to install MCEd tests and programs to deliver enhanced patient care. The surge in the number of advanced healthcare facilities will be critical to the industry’s final revenue during the forecast period.

Based on type, the multi cancer early detection industry segments are circulating tumor cells (CTC)-based tests, circulating tumor DNA (ctDNA)-based tests, extracellular vesicle (EV)-based tests, protein biomarker-based tests, metabolomics and epigenomics-based tests, and AI-enhanced multi-omics tests.

In 2024, the highest demand was listed in the circulating tumor DNA (ctDNA)-based tests segment due to the higher prescription-based availability of the tests. ctDNA is used to directly diagnose genetic alterations in blood that are linked to cancer.

According to research, more than 46.01% of the US population between the ages of 50 to 75 years is worried about a cancer diagnosis.

Multi Cancer Early Detection Market: Regional Analysis

North America to continue dominating the market during the forecast period

The global multi cancer early detection market will be led by North America during the forecast period. In 2024, the US was the leading revenue generator. The growing number of regional populations with cancer diagnoses across North America has fueled increased demand for MCED tests.

In addition to this, regional awareness about cancer prevalence, along with the advantages of early detection of cancer, has helped the North American industry thrive in the last few years. The presence of several critical biotechnology and pharmaceutical companies specializing in cancer treatment development has strengthened the region’s hold on the global map.

Europe is a prominent market contributing to over 30% of the global revenue in 2024. Increasing investments toward innovation of advanced diagnostic tools for cancer and rising healthcare expenditure, along with the presence of a universal and inclusive medical care plan for the ordinary population, will be crucial to the region’s expansion in the future.

In a recent event, the European Commission announced the launch of the European Cancer Imaging Initiative, which is a part of the broader Europe's Beating Cancer Plan, aiming to integrate Artificial Intelligence for improved and precise cancer diagnosis.

Multi Cancer Early Detection Market: Competitive Analysis

The global multi cancer early detection market is led by players like:

• Guardant Health
• Burning Rock Biotech Limited
• Perspectum
• Grail LLC
• Laboratory for Advanced Medicine Inc.
• Illumina Inc.
• Singlera Genomics Inc.
• Exact Sciences Corporation
• Quibim
• GENECAST
• Prenetics
• Foundation Medicine Inc.
• Harbinger Health
• AnchorDx
• Freenome

The global multi cancer early detection market is segmented as follows:

By End-Use

• Diagnostic Laboratories
• Hospitals
• Others

By Type

• Circulating Tumor Cells (CTC)-Based Tests
• Circulating Tumor DNA (ctDNA)-Based Tests
• Extracellular Vesicle (EV)-Based Tests
• Protein Biomarker-Based Tests
• Metabolomics and Epigenomics-Based Tests
• AI-Enhanced Multi-Omics Tests

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa